```
FILE 'HOME' ENTERED AT 13:56:17 ON 02 APR 2007
=>
file reg
Uploading C:\Program Files\Stnexp\Queries\Queries\10722104.str
```




```
chain nodes :
7  8  9  10  11  12  13  15  16
ring nodes :
1  2  3  4  5  6
chain bonds :
4-7  4-10  7-8  7-16  7-15  8-9  10-11  10-12  12-13
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6
exact/norm bonds :
4-7  7-8  7-16  7-15  8-9  10-11  10-12
exact bonds :
1-2  1-6  2-3  3-4  4-5  4-10  5-6  12-13
isolated ring systems :
containing 1 :


Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:CLASS  8:Atom  9:Atom  10:CLASS
11:CLASS  12:CLASS  13:CLASS  15:CLASS  16:CLASS
Generic attributes :
8:
Saturation              : Unsaturated



L1      STRUCTURE UPLOADED

=> dis l1
L1 HAS NO ANSWERS
L1                STR
```



Structure attributes must be viewed using STN`Express query preparation.

```
=> s l1 sam
L2             3 SEA SSS SAM L1

=> s l1 full
L3            41 SEA SSS FUL L1

=> file caplus

=> s l3
L4             2 L3

=> s l4 and pd<sept 2003
      23766849 PD<SEPT 2003
                 (PD<20030900)
L5             1 L4 AND PD<SEPT 2003

=> dis l5 bib abs hitstr

L5   ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2007 ACS on STN
AN   1999:388166  CAPLUS  Full-text
DN   131:44740
TI   Preparation of N-hydroxytetrahydropyridylsulfonylacetamides and related
     compounds as matrix metalloprotease inhibitors.
IN   Dack, Kevin Neil; Whitlock, Gavin Alistair
PA   Pfizer Limited, UK; Pfizer Inc.
SO   PCT Int. Appl., 149 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.          DATE
     ---------------     ----   --------    -------------------      --------
PI   WO 9929667           A1     19990617    WO 1998-EP6640           19981009 <--
         W:  AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
             DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE,
             KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW,
             MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR,
             TT, UA, UG, US, UZ, VN, YU, ZW
         RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,
             FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,
             CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     CA 2312935            A1     19990617    CA 1998-2312935          19981009 <--
     CA 2312935            C      20060314
     AU 9912301            A      19990628    AU 1999-12301            19981009 <--
     AU 741859             B2     20011213
     EP 1036062            A1     20000920    EP 1998-955494           19981009 <--
     EP 1036062            B1     20040102
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE,
             SI, LT, LV, FI, RO
     BR 9813360            A      20001017    BR 1998-13360            19981009 <--
     TR 200001611          T2     20001023    TR 2000-200001611        19981009 <--
     HU 200100845          A2     20010828    HU 2001-845              19981009 <--
     HU 200100845          A3     20021228
     JP 2001525396         T      20011211    JP 2000-524264           19981009 <--
     JP 3445242            B2     20030908
     NZ 504421             A      20020201    NZ 1998-504421           19981009 <--
```

AT 257151	T	20040115	AT 1998-955494	19981009	
PT 1036062	T	20040430	PT 1998-955494	19981009	
ES 2212373	T3	20040716	ES 1998-955494	19981009	
AP 930	A	20010126	AP 1998-1412	19981203	<--
W: BW, GM, GH, KE, MW, SD, UG, ZM, ZW					
ZA 9811112	A	20000605	ZA 1998-11112	19981204	<--
NO 2000002826	A	20000726	NO 2000-2826	20000602	<--
HR 2000000373	A1	20001231	HR 2000-373	20000605	<--
BG 104506	A	20010131	BG 2000-104506	20000605	<--
US 6495568	B1	20021217	US 2001-423359	20011012	<--
PRAI GB 1997-25782	A	19971205			
WO 1998-EP6640	W	19981009			

OS MARPAT 131:44740

GI



I

AB Title compds. [I; dotted line = optional double bond; A = C, CH; B = CH2, O, null; R1, R2 = H, (substituted) alkyl, alkenyl; R1R2C = (benzo-fused) C3-6 cycloalkyl group optionally incorporating O, SO, SO2, NR6; R3 = H, halo, R7, OR7; R4 = H, alkyl, alkoxy, CF3, halo; R6 = H, alkyl; R7 = (substituted) mono- or bicyclic ring system; m = 1, 2; n = 0-2; with the proviso that B is not O when A is C], were prepared as MMP inhibitors useful in the treatment of tissue ulceration, wound repair and skin diseases. Thus, Me 2-[4-(3-methyl-4-phenylphenyl)-1,2,3,6-tetrahydropyridin-1- ylsulfonyl]acetate (preparation given) was refluxed with NH2OH.HCl and K2CO3 in THF/MeOH to give N-hydroxy-2-[4-(3-methyl-4-phenylphenyl)-1,2,3,6- tetrahydropyridin-1-ylsulfonyl]acetamide. The latter inhibited matrix metalloproteinase 3 with IC50 = 16 nM.

IT 227304-22-5P 227304-26-9P 227304-35-0P
227304-36-1P 227304-51-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-hydroxytetrahydropyridylsulfonylacetamides and related compds. as matrix metalloprotease inhibitors)

RN 227304-22-5 CAPLUS

CN 2H-Pyran-4-carboxamide, 4-[[3,6-dihydro-4-(3'-methoxy-2-methyl[1,1'-biphenyl]-4-yl)-1(2H)-pyridinyl]sulfonyl]tetrahydro-N-hydroxy- (9CI) (CA INDEX NAME)



RN 227304-26-9 CAPLUS
CN 2H-Pyran-4-carboxamide, 4-[[4-(3'-ethoxy-2-methyl[1,1'-biphenyl]-4-yl)-3,6-dihydro-1(2H)-pyridinyl]sulfonyl]tetrahydro-N-hydroxy- (9CI) (CA INDEX NAME)



RN 227304-35-0 CAPLUS
CN 2H-Pyran-4-carboxamide, 4-[(4-[1,1'-biphenyl]-4-yl-3,6-dihydro-1(2H)-pyridinyl)sulfonyl]tetrahydro-N-hydroxy- (9CI) (CA INDEX NAME)



RN 227304-36-1 CAPLUS
CN 2H-Pyran-4-carboxamide, 4-[[4-(4'-ethoxy-2-methyl[1,1'-biphenyl]-4-yl)-3,6-dihydro-1(2H)-pyridinyl]sulfonyl]tetrahydro-N-hydroxy- (9CI) (CA INDEX NAME)



RN 227304-51-0 CAPLUS
CN 2H-Pyran-4-carboxamide, 4-[[3,6-dihydro-4-(2-methyl[1,1'-biphenyl]-4-yl)-1(2H)-pyridinyl]sulfonyl]tetrahydro-N-hydroxy- (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> s l4 not l5
L6            1 L4 NOT L5

=> dis l6 bib abs fhitstr

L6   ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2007 ACS on STN
AN   2004:467885  CAPLUS  Full-text
DN   141:38527
TI   Preparation of heteroarylsulfonylmethyl hydroxamic acids and amides and
     their use as protease inhibitors
IN   Becker, Daniel P.; Carroll, Jeffery N.; Fobian, Yvette M.; Grapperhaus,
     Margaret L.; Hansen, Donald W., Jr.; Heintz, Robert M.; Kassab, Darren J.;
     Massa, Mark A.; McDonald, Joseph J.; Nagy, Mark A.; Pitzele, Barnett S.;
     Rico, Joseph G.; Schmidt, Michelle A.; Spangler, Dale P.
PA   Pharmacia Corporation, USA
SO   PCT Int. Appl., 252 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.          DATE
     ---------------     ----   --------    --------------------     --------
PI   WO 2004048368        A2    20040610    WO 2003-US37942          20031124
     WO 2004048368        A3    20040812
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
             PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,
             TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
             BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
             ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
             TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     CA 2506796           A1    20040610    CA 2003-2506796          20031124
     AU 2003300800        A1    20040618    AU 2003-300800           20031124
     EP 1565459           A2    20050824    EP 2003-812052           20031124
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
     BR 2003016506        A     20051004    BR 2003-16506            20031124
     JP 2006513270        T     20060420    JP 2005-510336           20031124
     US 2004142979        A1    20040722    US 2003-722104           20031125
PRAI US 2002-429068P      P     20021125
     US 2003-504281P      P     20030919
     WO 2003-US37942      W     20031124
OS   MARPAT 141:38527
GI
```



I



II

AB Title compds. I [wherein A1 = H, OH, cycloalkyloxy, heterocyclyloxy; A2, A3 = independently H, (un)substituted (cyclo)alkyl(thio), alkenyl, alkynyl, heterocyclyl, etc.; or CA2A3 = (un)substituted cycloalkyl, heterocyclyl, such as tetrahydropyranyl; E1 = (un)substituted heteroaryl; E2 = (un)substituted cycloalkyl; E3 = a bond, O, CO, CO2, OCO, S, SO, SO2, OSO2, SO2O, C(=NH), C(=NOH), (un)substituted NH, CONH, NHCO, CONHNHCO, NHCONH, NHSO2, SO2NH, NHC(=NH), NHC(=NOH), C(=NH)NH, C(=NOH)NH, (carbonyl)alkyl, alkenyl, alkanoyl; E4 = H, halo, CN, (un)substituted (cyclo)alkyl, alkenyl, alkynyl, heterocyclyl; and salts thereof] were prepared as inhibitors of protease activity, particularly matrix metalloproteinase (MMP), TNF-α convertase, or aggrecanase activity. For example, coupling of 2-thiopheneboronic acid with 4-butoxybromobenzene gave 2-(4-butoxyphenyl)thiophene (58%), which was treated with Me disulfide and Oxone to afford the 5-(methylsulfonyl)thiophene derivative (58%). Reaction of the Me sulfone with t-Bu carboxylate anhydride using lithium bis(trimethylsilyl)amide provide the tert-Bu α-(thienylsulfonyl)acetate (89%). Tert-Bu 4-[[5-(4-butoxyphenyl)thien-2-yl]sulfonyl]tetrahydro-2H-pyran-4-carboxylate (91%) was produced by cycloaddn. of the acetate with bis(bromoethyl) ether in the presence of 18-crown-6. Deesterification (85%) with TFA, followed by amidation (100%) with O-(tetrahydro-2H-pyran-2-yl)hydroxylamine and O-deprotection (74%) with HCl gave II. The latter inhibited the human recombinant MMP-1, MMP-2, MMP-9, MMP-13, and MMP-14 cleavage of peptide substrates with Ki values of >1250 nM, 0.483 nM, 0.806 nM, 0.127 nM, and 466 nM, resp. Thus, I and their pharmaceutical compns. are useful for treating tissue destruction, fibrotic diseases, matrix weakening, defective injury repair, cardiovascular disease, pulmonary disease, kidney disease, liver disease, ophthalmol. disease, and/or CNS diseases (no data).

IT 701270-37-3P, 4-[[5-(4-Butoxyphenyl)thien-2-yl]sulfonyl]-N-hydroxytetrahydro-2H-pyran-4-carboxamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(protease inhibitor; heteroarylsulfonylmethyl hydroxamic acids and amides and their use as protease inhibitors)

RN 701270-37-3 CAPLUS

CN 2H-Pyran-4-carboxamide, 4-[[5-(4-butoxyphenyl)-2-thienyl]sulfonyl]tetrahydro-N-hydroxy- (9CI) (CA INDEX NAME)



```
=> log y
STN INTERNATIONAL LOGOFF AT 13:57:54 ON 02 APR 2007
```